All News
ILD Begins (8.29.2025)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com. This week news on vaccines, safety of acetaminophen and more.
Read Article
Guidance on aromatase inhibitor-associated bone loss with hormone-sensitive breast cancer
EurekAlert!
An updated joint position statement on the management of aromatase inhibitor-associated bone loss (AIBL) addresses the heightened fracture risk in women undergoing endocrine therapy for estrogen-responsive breast cancer, providing practical guidance for both osteoporosis specialists and oncologists.
Read Article
Repurposing & Pipeline (8.8.2025)
Dr. Jack Cush reviews the news, reports, pipeline and drug repurposing on this week’s podcast.
Read Article
Dermatomyositis Reviewed
Researchers from the University of Pennsylvania have published an open-access review of dermatomyositis (DM) - its manifestations, hallmark cutaneous features, etiopathogenesis and treatment options.
Read Article
A New RA Approval (8.1.2025)
Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA.
Read Article
Practical management of rheumatic immune-related adverse events with immune checkpoint inhibitors
Joint Bone Spine has published a full read review of the management of immune-related adverse events (irAEs) in patients receiving Immune checkpoint inhibitors (ICIs) for cancer.
Clinical Associations with Anti-RNA Polymerase III Antibodies
A systematic review of anti-RNA polymerase III antibodies (ARA) in systemic sclerosis (SSc) patients finds ARA positivity in only 9% of SSc patients, but come with a higher risk of many potentially worrisome outcomes.
Read Article
Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease A matched cohort study from the Veterans Health Administration shows that RA patients have a >50% increased risk of lung cancer, a 3-fold higher risk of lung cancer in RA-ILD. https://t.co/Gjn2M2CNAO https://t.co/F231nz57NY
Dr. John Cush RheumNow ( View Tweet)
Retrospective French Health Data System Immune Checkpt inhibitor (ICI) study. Of 172,363 ICI-Rx adult pts, ICI myotoxicities at 6 months ranged from 0.7% -0.9%. ICI myocarditis & myositis incidence was 0.3%- 0.6%, co-occurring in ∼13–23%. ICI myotoxicity- 1-mo fatality was https://t.co/kOGKM8lC0H
Dr. John Cush RheumNow ( View Tweet)
Review of cancer-associated myositis (CAM) & assoc myositis-specific or myositis-associated autoantibodies. 2017 meta-analysis 5 studies & 4538 pts w/ DM or PM, the cancer risk (SIR) for DM = 4.66, but PM = 1.75. Cancer risk ^^ w/ Low serum KL-6, TIF1γ, NXP2, HMGCR Abs https://t.co/xsOt4wPIXB
Dr. John Cush RheumNow ( View Tweet)
High cancer risk in myositis patients linked to autoantibodies- TIFF1g, NXP2, HMGCR. https://t.co/CECO78ESHi
Dr. John Cush RheumNow ( View Tweet)
RA has lower risk of colorectal cancer (CRC). Korean claims compared 41K RA pts 1:5 vs 204K non-RA. RA had signif. decreased risk for CRC (HR 0.89), main in seroneg RA (HR 0.79) but not seropos RA (HR 0.93). Inverse assoc mainly w/ rectal CA (HR 0.63) & women (HR 0.80). https://t.co/dudG4Is5oj
Dr. John Cush RheumNow ( View Tweet)
Guidance on aromatase inhibitor-associated bone loss with hormone-sensitive breast cancer
An updated joint position statement on the management of aromatase inhibitor-associated bone loss (AIBL) addresses the heightened fracture risk in women undergoing endocrine therapy for https://t.co/ZkvToBBGdB
Dr. John Cush RheumNow ( View Tweet)
Systematic review of 47 studies covering 1.5 million cases found that Dx of Crohns, SLE, Type I DM positively associated w/ incr risk of pancreatic, esophageal, colon, liver, and hepatobiliary cancers. MS assoc w/ lower risk of pancreatic, esophageal, rectal, & colorectal CA https://t.co/g0N5eHhJYj
Dr. John Cush RheumNow ( View Tweet)
Large metanalysis of TNFi use in immune-mediated inflammatory diseases (45 studies, 150K pts) shows no increased risk of de novo heart failure (HF), and no significant risk of HF worsening w/ TNFis. https://t.co/9sRVsMZ1kv https://t.co/igCdcQMVK3
Dr. John Cush RheumNow ( View Tweet)
Full read overview of Immune Checkpoint Inhibitors and their downside - immune related Adverse Events https://t.co/h1AzFaGVMz https://t.co/s75UdhE1HK
Dr. John Cush RheumNow ( View Tweet)
Japans IORRA study of 10,613 RA pts (2007-21) - 915 deaths from cancer (28%), lung Dz (22%), CV Dz (16%). Protective Rx were MTX and bDMARDs, while even low-dose glucocorticoids showed increased mortality risk. https://t.co/lV5WmC5l1X https://t.co/QncyqXSRE9
Dr. John Cush RheumNow ( View Tweet)
Cancer screening in RA - retrospective, matched cohort study of 1,614 RA vs 1,597 controls (mean 63 yrs); @ 5 yrs, RA had less cervical cancer screens (52% vs 58%) (aHR:0.83); but no decrease in screens for breast (aHR:0.98), prostate (aHR:0.99), or colorectal (aHR:1.04) CA https://t.co/NnxRnZcZwq
Dr. John Cush RheumNow ( View Tweet)
Practical management of rheumatic immune-related adverse events with immune checkpoint inhibitors
Joint Bone Spine has published a full read review of the management of immune-related adverse events (irAEs) in patients receiving Immune checkpoint inhibitors (ICIs) for cancer. https://t.co/i3FMOCbyNg
Dr. John Cush RheumNow ( View Tweet)
NEJM images: 55-year-old man with metastatic squamous-cell lung cancer Hx& 6-wk Hx firm, painful swelling RToe1 & RDIP3 w/ ulceration. Xray showed lytic lesions due to acrometastases - rare bony metastases distal to elbow or knee, that may may mimic gout or osteomyelitis https://t.co/1Fh1Cp9dm9
Dr. John Cush RheumNow ( View Tweet)
